Skip to main content

Catalyst Calendar

Scope

Thu, Aug 13, 2026

1 updates
PMN
4:00 PM

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

Announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company's Phase 1b trial of PMN310 in patients with early Alzheimer's disease (AD), including zero cases of amyloid-related imaging abnormalities-edema (ARIA-E) across all participants and genotypes, including APOE4 homozygotes....

Interim Data • Phase 1presentation Tue, Jun 30, 2026promisneurosciences.com

Mon, Aug 3, 2026

1 updates

Tue, Jul 28, 2026

1 updates
PMN
6:00 AM

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

No ARIA-E observed across all genotypes, including APOE4 homozygotes ARIA-H tracking background rates Early biomarker movement consistent with target engagement 12-month topline results expected in Q1 2027 Cambridge, Massachusetts, July 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq:...

Interim Data • Phase 1Results call Tue, Jul 28, 2026, 8:00 AM ETpromisneurosciences.com

Mon, Jul 27, 2026

1 updates
PMN
4:00 PM

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

Cambridge, Massachusetts, July 27, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will host a webinar on Tuesday, July 28, 2026, at 8:00 am ET, featuring Key Opinion...

Results Call • Phase 1Results call Tue, Jul 28, 2026, 8:00 AM ETpromisneurosciences.com

Tue, Jul 14, 2026

1 updates
PMN
2:30 AM

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers Represents one of the first quantitative measures of treatment-related effects on oligomer levels in a clinical trial Company on track to present six-month blinded interim data from its Phase 1b trial in the...

Presentation / Abstract • Phase 1AAIC poster presentation Tue, Jul 14, 2026, 7:30 AMpromisneurosciences.com

Thu, May 28, 2026

1 updates
PMN
10:13 AM

ProMIS Neurosciences to Participate in Upcoming Conferences in June

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one...

promisneurosciences.com